AI in fungal drug development: opportunities, challenges, and future outlook DOI Creative Commons

Yanjian Li,

Qiao Yue,

Yuanyuan Ma

et al.

Frontiers in Cellular and Infection Microbiology, Journal Year: 2025, Volume and Issue: 15

Published: May 21, 2025

The application of artificial intelligence (AI) in fungal drug development offers innovative strategies to address the escalating threat infections and challenge antifungal resistance. This review evaluates current landscape infections, highlights limitations existing therapies, examines transformative potential AI discovery development. We specifically focus on how can enhance identification new agents improve therapeutic strategies. Despite numerous opportunities for advancement, significant challenges remain, particularly regarding data quality, regulatory frameworks, complexities associated with process. aims provide insights into recent advancements technologies, their implications future development, necessary research directions effectively leverage improved patient outcomes.

Language: Английский

2024 FDA TIDES (Peptides and Oligonucleotides) Harvest DOI Creative Commons
Othman Al Musaimi, Danah AlShaer, Beatriz G. de la Torre

et al.

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(3), P. 291 - 291

Published: Feb. 20, 2025

In 2024, the FDA approved fifty novel drugs, including four peptides and oligonucleotides (TIDEs) (two pepTIDEs two oligonucleoTIDEs), highlighting their increasing importance as effective alternatives to traditional drug classes. TIDEs provide essential therapies for complex diseases, such genetic disorders, rather than merely addressing symptoms. addition oligonucleotide therapeutics various conditions, became first treatment Rett Syndrome in 2023 were also used treat Niemann–Pick disease type C (NPC) 2024. Interestingly, among strategies employed recent approvals enhance stability and/or delivery, prodrug approach, exemplified by palopegteriparatide pegulicianine, is emerging a more targeted precise therapeutic strategy. Additionally, Enhanced Stabilization Chemistry (ESC)-GalNAc platform has been expanded hepatic delivery of new drug, olezarsen. Furthermore, modifications ribose moiety oligonucleotides, 3′-amino substitution imetelstat, stability. This review examines TIDES 2024 based on chemical structure, medical targets, modes action, administration routes, common adverse effects. addition, it highlights how strategy improved targeting efficiency extended half-lives active drugs.

Language: Английский

Citations

5
AI‐Guided Design of Antimicrobial Peptide Hydrogels for Precise Treatment of Drug‐resistant Bacterial Infections DOI
Zhihui Jiang,

Jianwen Feng,

Fan Wang

et al.

Advanced Materials, Journal Year: 2025, Volume and Issue: unknown

Published: March 30, 2025

Abstract Traditional biomaterial development lacks systematicity and predictability, posing significant challenges in addressing the intricate engineering issues related to infections with drug‐resistant bacteria. The unprecedented ability of artificial intelligence (AI) manage complex systems offers a novel paradigm for materials development. However, no AI model currently guides antibacterial biomaterials based on an in‐depth understanding interplay between In this study, AI‐guided design platform (AMP‐hydrogel‐Designer) is developed generate biomaterials. This utilizes generative multi‐objective constrained optimization thiol‐containing high‐efficiency antimicrobial peptide (AMP), that functionally coupled hydrogel form network structure. Additionally, Cu‐modified barium titanate (Cu‐BTO) incorporated facilitate further cross–linking via Cu 2+ /SH coordination produce AI‐AMP‐hydrogel. vitro, AI‐AMP‐hydrogel exhibits > 99.99% bactericidal efficacy against Methicillin‐resistant Staphylococcus aureus (MRSA) Escherichia coli ( E. coli) . Furthermore, Cu‐BTO converts mechanical stimulation into electrical signals, thereby promoting expression growth factors angiogenesis. rat dynamic wounds, AI‐AMP significantly reduces MRSA load markedly accelerates wound healing. Therefore, strategy innovative solution precisely treat bacterial infections.

Language: Английский

Citations

2
Biofilm-Associated Candidiasis: Pathogenesis, Prevalence, Challenges and Therapeutic Options DOI Creative Commons

Valerie Amann,

Ann‐Kathrin Kissmann, Carolina Firacative

et al.

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(4), P. 460 - 460

Published: March 25, 2025

The rising prevalence of fungal infections, especially those caused by Candida species, presents a major risk to global health. With approximately 1.5 million deaths annually, the urgency for effective treatment options has never been greater. spp. are leading cause invasive significantly impacting immunocompromised patients and in healthcare settings. C. albicans, parapsilosis emerging species auris categorized as highly dangerous because their pathogenic potential increasing drug resistance. This review comparatively describes formation microbial biofilms both bacterial origin, including pathogens, thereby creating novel focus. Biofilms can further complicate treatment, these structures provide enhanced resistance antifungal therapies. Traditional agents, polyenes, azoles echinocandins, have shown effectiveness, yet development continues rise, necessitating exploration therapeutic approaches. Antimicrobial peptides (AMPs) such anti-biofilm Pom-1 Cm-p5 originally isolated from snails represent promising candidates due unique mechanisms action neglectable cytotoxicity. article discusses challenges posed characteristics important role virulence new like AMPs.

Language: Английский

Citations

0
Artificial intelligence in the discovery and modification of biological elements in medicinal plants DOI Creative Commons
Jing Zhang, Yixin Yang, Jinping Si

et al.

Medicinal Plant Biology, Journal Year: 2025, Volume and Issue: 4(1), P. 0 - 0

Published: Jan. 1, 2025

Language: Английский

Citations

0
How Machine Learning Helps in Combating Antimicrobial Resistance: A Review of AMP Analysis and Generation Methods DOI

Khalit Musin,

Elvina Asyanova

International Journal of Peptide Research and Therapeutics, Journal Year: 2025, Volume and Issue: 31(4)

Published: April 15, 2025

Language: Английский

Citations

0
Chemical Innovations of Antimicrobial Polymers for Combating Antimicrobial Resistance DOI
Zhangyong Si, Mary B. Chan‐Park

ACS Biomaterials Science & Engineering, Journal Year: 2025, Volume and Issue: unknown

Published: April 16, 2025

The global rise of antimicrobial resistance (AMR) has rendered many traditional antibiotics ineffective, leading to an urgent need for alternative therapeutic strategies. Antimicrobial polymers, with their ability rapidly kill bacteria by disrupting or crossing membranes and/or targeting multiple microbial functions without inducing resistance, offer a promising solution. This perspective explores recent innovations in the design and synthesis focusing on chemical motifs, structural derivatives, applications combating systemic topical infections. We also highlight key challenges translating these materials from laboratory research clinical practice, including issues related high dose required, bioavailability stability infection treatment, disperse biofilms localized management. By addressing challenges, polymers could play crucial role development next-generation therapeutics combat multidrug-resistant pathogens. attempts summarize significant insights advanced overcome AMR, offering potential pathways improve outcomes treating local

Language: Английский

Citations

0
Engineered multi-domain lipid nanoparticles for targeted delivery DOI

Z. Liu,

J. Chen, Mingkun Xu

et al.

Chemical Society Reviews, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

This review introduces a four-domain framework to dissect engineered lipid nanoparticles (LNPs) rationally and explores their programmability, in vivo behavior, emerging AI-driven strategies for design, simulation, clinical translation.

Language: Английский

Citations

0
AI in fungal drug development: opportunities, challenges, and future outlook DOI Creative Commons

Yanjian Li,

Qiao Yue,

Yuanyuan Ma

et al.

Frontiers in Cellular and Infection Microbiology, Journal Year: 2025, Volume and Issue: 15

Published: May 21, 2025

The application of artificial intelligence (AI) in fungal drug development offers innovative strategies to address the escalating threat infections and challenge antifungal resistance. This review evaluates current landscape infections, highlights limitations existing therapies, examines transformative potential AI discovery development. We specifically focus on how can enhance identification new agents improve therapeutic strategies. Despite numerous opportunities for advancement, significant challenges remain, particularly regarding data quality, regulatory frameworks, complexities associated with process. aims provide insights into recent advancements technologies, their implications future development, necessary research directions effectively leverage improved patient outcomes.

Language: Английский

Citations

0